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Abstract
Lipid-based nanoparticle technology has developed from chemical drug carrier into an efficient 
multifunctional siRNA tumor targeting delivery system. In this review, we start with an overview 
of the lipid-based nanomedicine history and the two classes of lipidic vectors for DNA or siRNA 
delivery. Then we discuss the features of lipid-based nanomedicine that lead to effective tumor 
targeting and the principles behind. We also discuss nanoparticle surface modification, classes of 
tumor targeting ligands, and other state-of-the-art strategies for enhancing endosome release 
primarily focused on lipid-based systems. At the end, we show that multifunctional self-assembled 
lipid-based nanoparticles could also be versatile delivery vehicles for cancer molecular imaging 
probes.
Keywords
Self-Assembly; Lipid; Liposome; Nanoparticles; Nanomedicine; siRNA; Tumor Targeting; 
Endosome Escape
1. INTRODUCTION
Drugs formulated in liposomes are considered the very first class of nanomedicine used in 
clinics. Liposomes are artificial cell-like vesicles that have an aqueous compartment inside 
the surrounding one or multiple lipid bilayers. The bilayer usually consists of a lipid 
component (usually a cationic lipid and/or a fusogenic lipid) and cholesterol. Some may 
further contain a polyethylene glycol-lipid conjugate for surface protection.1 The aqueous 
compartment and the lipid bilayer have both been used to carry drugs. By formulating 
doxorubicin into liposomal dosage form, it can increase the tumor uptake and reduce the 
cardio-toxicity.2,3 For the drugs with very poor solubility such as paclitaxel, loading the drug 
into the bilayer compartment can increase the delivering dose.4,5 For some drugs, such as 
camptothecins that are not stable under physiological pH, formulation into liposomes can 
also protect them from degradation.6,7 Furthermore, it can improve the pharmacokinetic 
profile primarily by increasing the circulation time of the drug.8
Lipid-based systems have also been developed for poly- or oligo-nucleotide delivery for 
decades. In 1987, Felgner et al.9 showed that lipofection, i.e., cationic lipid mediated 
transfection, is more efficient for delivering DNA into cells than calcium phosphate10,11 or 
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DEAE-dextran.12 Later, various cationic lipid formulations such as the popular 
Lipofectamine13,14 or cardiolipin analogs15,16 have been developed and used extensively for 
in vitro DNA or siRNA delivery.
An important milestone for lipid-based nanomedicines is the clinical trial for liposome-
mediated gene therapy conducted in 1992. This clinical trial used a liposome formulation 
consisting of a cationic derivative of cholesterol, 3-β-[N-(N′,N′-dimethylaminoethane)-
carbamoyl] cholesterol and dioleoylphosphatidylethanolamine (DC-Chol/DOPE) to transfer 
a xenogenic MHC class I antigen gene to the cutaneous melanoma lesions.17 Although the 
transfection efficiency, the duration of expression, and the overall therapeutic effect was not 
as promising as anticipated, no adverse clinical effects were observed.18 There were other 
clinical trials for cystic fibrosis using other cationic lipids.19,20
The discovery of RNA interference has brought a new category of therapeutics that can be 
used for genetic diseases,21–25 viral infections,26–31 or cancers by inhibiting various 
pathways. Compared to delivering plasmid DNA for expressing short-hairpin RNA (shRNA) 
in cells, delivering synthetic siRNA can silence protein expression and is more favorable in 
terms of drug delivery. The great advantage of siRNA therapy is that the site of action is the 
cytoplasm, not the nucleus. Lipid-based systems and other non-viral vectors are excellent 
vehicles for siRNA delivery.
2. CLASSES OF LIPIDIC VECTORS
DNA or siRNA delivery systems can be divided into viral and non-viral vector systems. 
Based on the type of the target disease, local or systemic administration is a factor of 
consideration. Viral vectors have been used for both systemic and local administrations. The 
strategy is, by genetic engineering, replacing pathogenic viral genes with desired genes or 
shRNA expression cassette. One great advantage of using viral vectors is that some viral 
vectors such as lentiviral and retroviral vectors can achieve stable long term expression due 
to their host genome-insertion nature.32 In addition, viral vectors are generally more efficient 
in terms of expression level. However, immunogenicity and other safety issues are always 
the major concerns of using viral based systems, especially in humans. For the field of tumor 
targeting siRNA therapy, since stable long term expression is not needed and the site of 
action for siRNA is only the cytoplasm, non-viral vectors are more favorable.
There are different types of non-viral vectors for siRNA or DNA delivery such as polymers, 
block co-polymers, proteins, or peptides.33–36 Various designs have been established based 
on either chemical conjugation or self-assembly processes. Self-assembled nanomedicines 
are more desirable due to their easy preparation and potential for scale-up manufacturing. 
Desimone et al.37–40 established an imprint lithographic technique called PRINT™ (Particle 
Replication In Non-wetting Templates) for nanoparticle production. A variety of materials 
including synthetic polymers, hydrogels, active pharmaceutical ingredients, and proteins41 
could be made into shape-specific, monodisperse, and surface modifiable nanoparticles.37 
Bioactive agents including proteins, DNA, and small-molecule therapeutics42 have also been 
encapsulated into PRINT™ nanoparticles. There are also other non-viral physical methods 
such as hydrodynamic injection,43–45 electroporation,46–48 and particle bombardment49 that 
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could be used for local DNA or siRNA delivery. In this review, we will primarily focus on 
lipid-based self-assembled nanoparticles with tumor as the target disease.
2.1. Lipoplex
There are two main types of self-assembled lipid nanomedicines, one is the traditional type 
that formed simply by mixing positively charged liposome with negatively charged DNA or 
siRNA to make a complex. These types of reagents have been extensively used for in vitro 
gene transfection or silencing. The other type is a more sophisticated lipopolyplex 
nanoparticle such as the LPD (liposome-polycation-DNA) nanoparticles designed in our lab 
in the mid 90s.50
Verma et al. reported the first lipoplex mediated in vivo tumor siRNA delivery via 
intraperitoneal (i.p.) injection to a HCT116 colon cancer xenograft model with commercially 
available Oligofectamine (Invitrogen, Carlsbad, CA). They showed successful β-catenin 
expression reduction and HCT116 tumor growth inhibition.51 Sorensen et al. used DOTAP 
(N-[1-(2,3-dioleoyloxy)]-N-N-N trimethyl ammonium propane) liposomes to make lipoplex 
for systemic siRNA delivery.52 They showed inhibited exogenous green fluorescent protein 
expression in liver and spleen via systemic intravenous (i.v.) injection and endogenous tumor 
necrosis factor expression in macrophages via i.p. injection.
The problem for lipoplex is that the complex is not very stable. Especially when diluted in 
the blood circulation after injection. The lipoplex is usually made fresh immediately before 
use. Also, the works mentioned above did not really target siRNA to solid tumors via i.v. 
injection. To achieve siRNA solid tumor targeted delivery via systemic i.v. injection, a more 
sophisticated system that can produce a nanoparticle stable long enough before reaching the 
solid tumor is required.
2.2. LPD
Unlike a liposome that has an aqueous phase inside the particle, LPD nanoparticles consist 
of a solid core inside of the lipid bilayer.53 The core formation is a self-assembly process 
driven by charge–charge interaction. In the LPD formulation designed in our lab, we use 
FDA approved protamine with the help of a high molecular weight calf thymus DNA to 
condense DNA or siRNA into a solid core.54,55 Protamine is a highly positive charged 
arginine-rich nuclear protein from salmon sperm. Its natural function is to replace histones in 
the haploid phase of spermatogenesis and stabilize the DNA. With slightly excess amounts 
of negatively charged DNA or siRNA to positively charged protamine, the solid core 
remains negatively charged and thus allows further coating with positively charged DOTAP/
cholesterol cationic liposomes. The self-assembled LPD nanoparticles were further modified 
by post-inserting either DSPE-PEG for surface protection or DSPE-PEG-anisamide for 
targeting to the sigma receptor (Fig. 1).54–56
With a similar approach, Harashima group used poly-L-lysine to condense shRNA encoding 
plasmid DNA or siRNA into their octaarginine modified Multifunctional Envelope type 
Nano Device (MEND) (Fig. 2). The octaarginine function for cell penetration will be 
discussed later. In this work, over 80% of luciferase gene expression silencing in HeLa cells 
was reported.57,58
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Besides lipoplex and LPD formulation, Zimmermann et al. used a stable nucleic acid lipid 
particles (SNALP) formulation consisting of 3-N-[(ω-methoxypoly(ethyleneglycol)2000) 
carbamoyl]-1, 2-dimyristoyloxy-propylamine (PEG-C-DMA), 1,2-dilinoleyloxy-N,N-
dimethyl-3-aminopropane, (DLin DMA), 1,2-distearoyl-sn-glycerol-3-phosphocholine 
(DSPC) and cholesterol, in a 2:40:10:48 molar ratio to deliver siRNA against apolipoprotein 
B (apoB) in the liver. In this formulation, the siRNA was encapsulated within the liposomes. 
More than 80% silencing of apoB mRNA and apoB-100 protein could be achieved with a 
single 1 mg/kg dose in non-human primate.59
3. FEATURES THAT LEAD TO EFFECTIVE TUMOR TARGETING
For targeting nanoparticles to solid tumors, there are several important barriers that have to 
be overcome. The pharmacokinetic and pharmacodynamic profiles of nanoparticles are 
completely different from conventional small chemical drugs or some protein drugs that are 
usually eliminated or metabolized by the kidneys, liver, or lungs.60 Nanoparticles are cleared 
from the blood circulation primarily by the reticuloendothelial system (RES), especially the 
Kupffer cell in the liver 61 and the macrophages in the spleen. After injecting the 
nanoparticles into the blood circulation, opsonins such as IgM, IgG, fibronectins, or 
complement C3 will absorb to their surface. Phagocytic cells will recognize the opsonins 
and will rapidly and effectively take up the opsonized nanoparticles. The uptake of the 
nanoparticles by the tumor is a slower and less efficient process. Thus, the RES uptake 
represents a major “kinetic barrier” for drug delivery to the tumor by nanoparticles. Once the 
nanoparticles arrive at the tumor, there are other “physical barriers” preventing the cargo 
drugs from entering the cytoplasm. With appropriate design, self-assembled lipid 
nanomedicines have been successfully used for siRNA tumor targeting delivery. Li et al.55,62 
showed that by taking advantage of the enhanced permeability and retention (EPR) effect of 
the tumor (see below), PEGylated LPD could accumulate up to 60–80% injected dose per 
gram of tissue in the H460 lung cancer xenograft model (Fig. 3). With the help of a targeting 
ligand–anisamide, significant siRNA uptake and almost complete oncogene silencing and 
significant tumor growth inhibition in vivo were observed. By delivering MDM2, c-myc, 
and VEGF siRNA combination, significant pulmonary metastasis inhibition in a B16F10 
murine melanoma model was also observed (Fig. 4). In the following sections, we will 
discuss in detail how self-assembled nanoparticles overcome these barriers.
3.1. EPR Effect, PEGylation, Optimal Size
Tumor cells are rapidly differentiating and growing cells. They require a large amount of 
nutrient supply. Angiogenesis as induced by growth factors, e.g., VEGF, is important for 
tumor growth.63 Neovessels in the tumor are usually leaky and not well organized. However, 
the degree of leakiness is highly tumor dependent and could vary significantly. Matsumura 
and Maeda64 discovered that due to the leakiness of the vasculature in the solid tumor, 
macromolecules and colloidal nanoparticles that are too big to penetrate normal blood 
vessels could penetrate these leaky vasculature and accumulate at the tumor site. This is so 
called Enhanced Permeability and Retention (EPR) effect. Lacking lymphatic drainage 
might also contribute to the enhanced retention effect.64–66 To take advantage of the EPR 
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effect, nanoparticles must be within an optimal size range. The optimum diameter should be 
around 100 nm.67 However, it is dependent on the leakiness of the tumor vasculature.
Nanoparticles need to stay in the blood circulation long enough to overcome the kinetic 
barrier for extravasating the leaky tumor vasculature. As previously mentioned, the primary 
elimination mechanism for nanoparticles is the uptake by phagocytic cells after opsonization 
of the nanoparticles. Modifying the nanoparticle surface with carbohydrate or polyethylene 
glycol (PEG) is a common strategy for protecting and shielding the surface charge.68 Studies 
have shown that PEGylated colloids69,70 and stealth liposomes55 could stay in the blood 
circulation up to 6–10 h in mice and 40 h in humans.71
3.2. Targeting Ligands
EPR effect is important in guiding the nanoparticles to tumor tissue, but EPR effect is not 
enough for delivering siRNA into the cancer cells. There still remains two physical barriers, 
cell membrane and endosome membrane, that prohibit siRNA from entering the cytoplasm. 
Drugs or siRNA that stay outside of the cancer cells are not bio-available and will not show 
therapeutic effect. Nanoparticles with a structure too stable may stay in the tumor 
extracellular matrix without releasing payload drugs. For example, a stealth liposomal-
cisplatin formulation (SPI-077) accumulated efficiently at the tumor site, but it showed 
minimum therapeutic effect compared to free cisplatin.72 In order to prompt cancer cells to 
take up nanoparticles, targeting ligands are needed for triggering receptor mediated 
endocytosis. There are various types of targeting ligands being used for tumor targeting, 
including peptides, proteins, antibodies (including Fab, scFv, etc.), aptamers, and small 
molecular weight ligands, etc.
3.2.1. Peptide Ligands—Binding motifs between ligands and receptors usually involves 
only several amino acids. Based on this concept, investigators have establish phage display 
libraries to select special amino acid sequences that show strong binding affinities to tissues, 
cells, or organs of interests.73 This method has been established and improved for decades. 
Increasing numbers of peptide ligands have been identified with high affinities against neo-
vasculature, various kinds of cancer cells, proteins, receptors, organs and even lymphatic 
vessels.74 For example, the RGD (Arg-Gly-Asp) motif that shows great binding around 1 
nM has been used for targeting various drugs or nanoparticles to either tumor neo-
vasculature or cancer cells that express integrin αvβ3 cell surface receptor.75–77 NGR (Asn-
Gly-Arg) peptide targeting aminopeptidase N (APN, CD13) is another example for peptide 
ligand.78 There are also other non-specific cell penetrating peptides for drug delivery 
systems. They include the famous HIV-1 Tat, Drosophila Antennapedia transcription factor, 
herpes simplex virus type-1 VP22 transcription factor, or even simple oligoarginine (R8, R9) 
peptides.79,80
3.2.2. Antibodies (Including Fab, scFv, etc.)—Antibodies (mostly IgG) have been 
extensively used in biological laboratories due to their high binding affinity to specific 
epitopes. Humanized antibodies can be used solely or combined with other chemotherapy 
agents for cancer therapy. Two great examples are the FDA approved anti-Her2/neu 
monoclonal antibody Herceptin® for breast cancer and the anti-VEGF monoclonal antibody 
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Avastin® for metastatic colorectal cancer. Taking advantage of their binding activity to 
cancer cell membrane proteins, Herceptin has also been used in targeting liposomes to breast 
cancer xenografts.81–85
IgG antibodies usually have a molecular weight around 150 kDa. In order to make them 
smaller to either increase the biological production efficiency or reduce the chances to 
generate immune response, several smaller versions of antibodies have been adapted.86 For 
example, removal of the Fc region of the IgG to become the Fab fragment, or combination of 
the variable regions of both light and heavy chains into a single chain peptide antibody 
(scFv) is commonly used. Fab and scFv can further be engineered into dimer, trimer, or 
tetramer forms to provide stronger multivalent binding.
3.2.3. Transferrin—Transferrin is an iron transporting protein that can specifically react 
with its receptor (Tf receptor) that is expressed in various tissues. Due to the rapid growth of 
cancer cells, Tf receptors are over-expressed on various kinds of cancers. Anti-Tf receptor 
antibody87,88 and transferrin have both been used as ligands for targeting liposomes to 
tumors89,90 or even brain cells.91
3.2.4. Small Molecule Ligands (Folic Acid, Anisamide)—Small molecule ligands 
that have good binding affinity and specificity are also suitable for tumor targeting, although 
they are relatively rare. The advantages of using small molecule ligands compared to small 
peptides, proteins, or antibodies may include: easy synthesis, more tolerant to chemical 
modification/conjugation, low immunogenicity, and stable for long-term storage.
The vitamin, folic acid, is the high affinity natural ligand for the folate receptor which is 
over-expressed in a wide range of human cancers, including ovary, lung, breast, 
endometrium, kidney, and brain cancers. Drugs including protein toxins, chemotherapeutic 
agents, oligonucleotides, radioimaging/therapeutic agents, MRI contrast agents, 
liposomes,92 etc. have been modified and targeted with folic acid to various tumors.93–95 
Anisamide96 and haloperidol97,98 are good small molecule ligands for cancer cells over-
expressing the sigma receptor. They include melanoma, non-small cell lung carcinoma, 
breast tumors of neural origin, and prostate cancers.97,99–101 The LPD tumor targeting work 
done in our lab uses mostly anisamide as the targeting ligand.54–56,62
3.2.5. Aptamers—Aptamers are nucleic acid-based ligands ranging in size from 20 to 80 
bases (6 to 26 kDa). They were mostly identified through a procedure called “systemic 
evolution of ligands by exponential enrichment” (SELEX). Due to their unique nucleotide 
sequences, aptamers fold into unique 3D structures and are able to recognize, with high 
affinity, various molecules including proteins, sugars, phospholipids, or even small 
chemicals. One aptamer recognizing VEGF (Macugen®) has been approved by FDA as a 
therapeutic drug for the treatment of age-related macular degeneration (AMD).102 The 
aptamer that recognizes the prostate-specific membrane antigen is so far the most successful 
tumor targeting aptamer. With this aptamer, poly(d,l-lactide-co-glycolide)-block-
poly(ethylene glycol) (PLGA-b-PEG) nanoparticles,103 aptamer-siRNA chimera,104 and 
quantum dots105 have been delivered to prostate cancer xenografts.
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There are additional ligands under development such as protein scaffolds (e.g., affibody and 
monobody, which are protein domain-based frameworks).106 The options for tumor targeting 
ligands will keep growing. Since some targeting ligands may have their biological functions 
after binding to the receptors, choosing them carefully is important. For example, if the 
ligand serves as an agonist, it may promote cancer cell growth. It might not be a good ligand 
for tumor targeting.
3.3. Endosome Escape, Proton Sponge Effect, HII Phase, Ion-Pairs
Getting the nanoparticles endocytosed is not a major issue. The challenge that remains for 
the siRNA delivery field is how to bring the siRNA out of the endosome. For lipid-based 
systems, the mechanism through which cationic lipoplex can trigger endosome release has 
been proposed by Xu and Szoka.107 They proposed that in the endosome, the cationic lipid 
of the lipoplex can form ion-pairs with the anionic endosomal membrane. By excluding the 
interfacial water molecules, the ion-pairs destabilize the endosomal membrane. Furthermore, 
binding of cationic lipid with anionic lipids can form the inverted hexagonal HII phase, 
proposed by Cullis et al.,108 and leads to membrane fusion and release of cargo. Generally 
speaking, cationic lipids with smaller and less charged head groups and more bulky acyl/
alkyl chains favor the HII phase formation.109 This is probably the reason why DOTAP 
(containing two C18:1 acyl chains) is used quite often In liposome transfection formulation 
as a cationic lipid but DSTAP (1,2-distearyl-3-trimethylammonium propane, a close analog 
of DOTAP but with two C18:0 chains) is not.
Cationic lipid is not the only category of cationic molecules that can form ion-pairs with the 
endosomal membrane. Protein transduction domains such as HIV Tat, Drosophila 
Antennapedia transcription factor, herpes simplex virus type-1 VP22 transcription factor, or 
oligo-arginines (R8 or R9) also show similar activity. It is interesting to know that these 
peptides all have multiple arginines but not lysines in their sequences. Sakai and Matile110 
showed that this is because the charged groups of both the cationic guanidinium group of the 
poly-arginine and the anionic phosphate group of the endosomal membrane phospholipids 
contain delocalized electrons. They form stronger charge-charge interaction and hydrogen 
bonding than the interaction between phospholipid and lysine which does not contain 
delocalized electrons. Also, protamine used in the LPD formulation mentioned earlier also 
contains many arginines but not lysine.
Unlike cationic lipids that possess an intrinsic fusogenic property, polyplex formed by 
polymeric cationic carriers such as polyethyleneimine (PEI)111–114 shows a “proton sponge 
effect” for endosome destabilization.115–118 The polyplex has many crowded 1°-, 2°- and 3°-
amines. Due to the crowding effect, these amines show different pKa within the endosomal 
pH range and serve as a buffering “proton sponge.” After endocytosis, the pH inside the 
endosome should drop from physiological pH 7.4 to around pH 5 during the endosome-
lysosome maturation process. Due to the presence of the “proton sponge,” the pH would not 
drop as expected. The ATP-dependent proton-pump on the endosomal membrane would 
transport extra protons and chloride ions (counter ions), resulting in an increase in the 
osmotic pressure. Eventually, the endosome would swell and burst due to the large amount 
of water influx and the polyplex could be released. Polymers containing crowded histidines 
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(imidazoles) or morpholinos also show a similar buffering effect.119 The buffering effect 
may also play a role in protecting siRNA from degradation during the early endosome to late 
endosome transport process.
Verkman et al.118 did an elegant piece of work visually showing the accumulation of 
chloride ions in the endosomes and the release of chloride ions after endosomes burst. 
However, they did not show exactly that the cargo was efficiently released. The endosome 
burst and release of chloride ions does not necessary accompany the release of the cargo of 
the polyplex.
4. ENDOSOME ESCAPE (A PROGRESSING TECHNOLOGY)
Although some self-assembled lipid siRNA tumor targeting nanoparticles already show 
therapeutic effects in some xenograft mouse models, the endosome escape is still inefficient. 
Most of the siRNA delivered to tumor cells are still trapped inside the endosome 
compartment (Li et al. unpublished observation). There might be several reasons for the 
problem: PEG dilemma, lack of ion-pair formation, not small enough particle size, and 
insufficient de-assembly of the particles.
4.1. PEG Dilemma
As previous mentioned, PEGylation is the most commonly used method to protect the bare 
surface of nanoparticles. However, as PEG chains prevent the attachment of opsonins, they 
also impede the contact between nanoparticles and the target cells. Inside the endosome, 
PEG may also prohibit the interaction between the cationic lipids of the lipoplex and the 
anionic endosomal membrane. This is so called “PEG dilemma.”120 Sophisticated designs 
such as tunable stealth liposomes,121 cleavable PEG-lipid linker,120 or acid labile PEG 
molecule might help dealing with this dilemma.
4.2. Enhance Endosome Escape
Boeckle et al.122 have done an interesting study on the effect of free PEI in transfection. 
They compared the gene transfer efficiency between purified PEI-DNA polyplex and un-
purified PEI-DNA polyplex mixture (containing unbound PEI molecules). The result shows 
that without the presence of unbound free PEI, the gene transfer efficiency decreased 
dramatically. By applying free PEI 4 h after purified PEI-DNA polyplex transfection, they 
could rescue the gene transfer efficiency, probably by helping the previously transfected 
purified PEI-DNA polyplex escape from the endosome. This shows that free unbound 
cationic polymers such as PEI or poly-arginine may play a critical role in disrupting 
endosomes by forming ion-pairs with the anionic endosomal membrane. Poly-arginine may 
have stronger activity than PEI due to their ion-pair formation activity described by Sakai 
and Matile.110 If a nanoparticle formulation could sufficiently release free cationic polymers 
inside the endosome, there would be a great chance that the siRNA delivery be significantly 
improved.
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4.3. Particle de-Assembly and Smaller Particles
Besides endosome escape, de-assembly of nanoparticles is also essential for sufficient 
siRNA release. If the structure of the nanoparticles is so stable that they will not release the 
siRNA inside, the siRNA will not be bio-available. De-assembly may take place either in the 
endosome or in the cytoplasm after the endosome escapes. Ideally, it should take place in the 
endosome with the release of endosome disrupting cationic materials, because, even though 
the endosome is disrupted or burst, the “hole” opened on the endosomal membrane may not 
be large enough to allow intact nanoparticles to pass through. The LPD nanoparticles 
established by our lab have a particle size around 120 ~ 150 nm. If the particle size could be 
smaller (perhaps under 100 nm), not only could they escape from the endosome more 
efficiently, the required siRNA dose for tumor killing may also decrease. Furthermore, they 
may reach those tumors with less leaky vasculatures.
5. THERANOSTIC NANOMEDICINES
Tumor imaging is a very powerful clinical technique for tumor detection and therapeutic 
effect monitoring. With the development of multifunctional nanoparticles that can carry both 
drugs and imaging agents in the same formulation,123 monitoring cancer therapeutic effects 
while delivering the therapeutic agents at the same time has become possible. Self-
assembled lipids-based nanoparticles could be one of these multifunctional delivery systems 
for both therapeutic siRNA and a diagnostic agent. This is the so called theranostic smart 
nanomedicines. Since tumor cells will receive therapeutic siRNA and the diagnostic agent at 
the same time, cell-specific real-time monitoring of the therapeutic event can be achieved. 
By monitoring whether the tumor is undergoing apoptosis in the early phase of a given 
treatment, physicians could decide to either continue the treatment or changing the treatment 
strategy.
Apoptosis is a complex mechanism that involves various pro-apoptotic and anti-apoptotic 
molecules inside the cell. There are several methods for detecting apoptosis in vitro now, 
such as staining for the appearance of phosphatidylserine (PS) using annexin V or detecting 
the activation of caspase-3 which is an early apoptosis event. Annexin V is a human 
placental anticoagulant protein with four repeats each containing a putative Ca2+ dependent 
binding site for PS. PS was originally distributed in the inner plasma membrane. During 
apoptosis, the asymmetry of the cell membrane is disrupted, which results in the flip-out of 
PS and can be stained with annexin V as a marker of apoptosis. Several reports have 
demonstrated that annexin V labeled with indium-111, technetium-99 m, iodine-123, 
iodine-124 or fluoride-18 can be used for in vivo study.124–128
Monitoring caspase-3 activity is another widely applied in vitro apoptosis monitoring 
method. Several reports and commercially available kits have been designed based on the 
peptide sequence DEVD (asp-glu-val-asp) found in poly-ADP-ribose-polymerase (PARP), a 
natural substrate of caspase-3. Linking the DEVD sequence with two fluorescent proteins 
for fluorescence resonance energy transfer (FRET) (Fig. 5),129 a fluorophore with a 
quencher,130 or two subunits of luciferase131 as probes for apoptosis have been 
demonstrated in vitro or in vivo.
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Many recent reports demonstrate that liposomes can be loaded with gadolinium (Gd)132–134 
or Maghemite (γ-Fe2O3) nanocrystals135 for magnetic resonance imaging, quantum dots136 
for optical imaging, or64 Cu for positron emission tomography (PET) imaging.137 Among 
all the imaging techniques, MRI can provide good resolution and PET is very sensitive with 
moderate resolution. Both of them have almost no tissue depth limitation, but, so far, they 
can only show the size and location of the tumor. Monitoring therapeutic efficacy based on 
the change in tumor size may not be early enough. On the other hand, taking advantage of 
the FRET with only fluorescence dyes or involving quantum dots as a donor,138 
fluorescence imaging is capable of generating a signal that would change its profile. Thus, it 
has the potential for apoptosis monitoring.
Fluorescence with the wave length within visible range has been routinely used in 
fluorescence microscopy or intravital microscopy. But when it comes to in vivo imaging of 
the whole animal without any invasive procedure, high absorbance or scattering of the 
visible light by the tissues becomes a major issue. Inside the tissue, hemoglobin is the 
primary absorber for visible lights; water and lipids are the major absorbers of the infrared 
light. However, the absorbance coefficients of hemoglobin, water, and lipids are small within 
the near infrared (NIR) range (around 600 ~ 900 nm). Besides, imaging in the NIR range can 
also reduce the auto-fluorescence background from tissue and thus provide improved signal 
to noise ratio. Using advanced imaging methods such as fluorescence molecular tomography 
(FMT) with near infrared fluorophores can provide 7 to 14 cm penetration in tissue,139 
which could be useful in clinical practice.
6. CONCLUDING REMARKS
Lipid-based nanomedicines have been known for their high biological compatibilities. Their 
pharmacokinetics and pharmacodynamics profiles are also well studied. This is a solid 
foundation for further development of advanced self-assembled lipid nanomedicines. The 
work done by our lab and other groups has shown that self-assembled lipid nanomedicines 
can specifically deliver siRNA to tumors in several xenograft and syngeneic models. 
Although the endosome escape of siRNA cargo still has room for improvement, the existing 
results are already promising. Finally, theranostic nanomedicine will be a new generation 
drug with high demand. Self-assembly nanoparticles are capable of carrying various cargos 
as long as these cargos meet the pre-requirement of the self-assembly process. Another 
advantage is that the manufacturing process of self-assembled lipid nanomedicines could be 
easily scaled-up. This also makes self-assembled lipid nanomedicines a versatile 
multifunctional delivery system for theranostic nanomedicine design.
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(A) Preparation of the PEG and PEG-anisamide (PEG-AA) modified LPD. (B) Chemical 
structures of DSPE-PEG2000 and (C) DSPE-PEG2000-anisamide. Reproduced with 
permission from [54], S. D. Li and L. Huang, Targeted delivery of antisense 
oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharm. 3, 579 
(2006). © 2006.
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The multifunctional envelope-type nano device (MEND) has a condensed nucleotide core 
coated with lipid envelope. The lipid envelope contains membrane fusogenic lipids and is 
further modified with PEG, targeting ligand and protein transduction domain peptides. 
Reproduced width permission from [58], K. Kogure et al., Multifunctional envelope-type 
nano device (MEND) as a non-viral gene delivery system. Adv. Drug Deliv. Rev. 60, 559 
(2008). © 2006.
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Tissue distribution study of siRNA formulated in different LPD formulations. (A) FAM-
labeled siRNA was formulated into LPD formulations and i.v. injected into nude mice 
through tail vein. After 4 hours, tumor and major organs were collected. FAM fluorescence 
signals were detected by Xenogen IVIS-100 imaging system. (B) Quantitative results of 
FAM-siRNA tissue distribution. Data =mean ±SD, n = 3–4. NP, nanoparticles. Reproduced 
with permission from, [55], S. D. Li et al., Tumor-targeted delivery of siRNA by self-
assembled nanoparticles. Mol. Ther. 16, 163 (2008). © 2008.
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LPD nanoparticles (NP) mediated siRNA delivery for metastatic tumor growth inhibition. 
Lung–homing B16F10 melanoma cells were i.v. injected into mice. 10 days later, mice were 
i.v. injected with siRNA twice (0.45 mg/kg, MDM2/c-myc/VEGF = 1:1:1, weight ratio). 
After six days, the mice were sacrificed and observed for melanoma growth in the lung. 
Only the mice received siRNA in targeted NP showed significant tumor growth reduction. 
Reproduced with permission from [62], S. D. Li et al., Efficient oncogene silencing and 
metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16, 942 (2008). © 2008.
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DEVD FRET probe containing DEVD as the specific cleavage site for caspase-3, Cyan 
Fluorescent Protein (CFP) as the FRET donor, and Yellow Fluorescent Protein (YFP) as the 
FRET acceptor. (A) Without the presence of caspase-3, CFP and YFP are linked by DEVD 
peptide. Upon CFP excitation, the energy was transferred to YFP by FRET. (B) With the 
presence of caspase-3, the DEVD linker was cleaved and the FRET between CFP and YFP 
was disappeared. (C) DLD-1 cell expressing DEVD FRET probe was treated with 1 μM 
staurosporine for inducing apoptosis. The changes of CFP/YFP and FRET/YFP emission 
ratio indicate the cleavage of the DEVD FRET probe. Reproduced with permission from 
[129], C. L. O’Connor et al., Intracellular signaling dynamics during apoptosis execution in 
the presence or absence of X-linked-inhibitor-of-apoptosis-protein. Biochim. Biophys. Acta. 
1783, 1903 (2008). © 2008.
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